পৃষ্ঠা 1 থেকে 18 ফলাফল
The present invention relates to substituted 4(5)-(1-indanyl and 1-indanylmethyl and 1-indanylmethylen)imidazoles and 4(5)-[1-(1,2,3,4-tetrahydronaphthyl and 1,2,3,4-tetrahydronaphthylmethyl and 1,2,3,4-tetrahydronaphthylmethylen]imidazoles and to their isomers, pharmaceutically acceptable salts and
The present invention relates to substituted 4(5)-(1-indanyl and 1-indanylmethyl and 1-indanylmethylen)imidazoles and 4(5)-[1-(1,2,3,4-tetrahydronaphthyl and 1,2,3,4-tetrahydronaphthylmethyl and 1,2,3,4-tetrahydronaphthylmethylen]imidazoles and to their isomers, pharmaceutically acceptable salts and
TECHNICAL FIELD
The present invention relates to ion channel activating agents. More particularly, the present invention relates to a particular class of chemical compounds that has proven useful as openers of SK.sub.Ca and IK.sub.Ca channels. In further aspects, the present invention relates to the
The present invention relates to compounds which potentiate neurotransmission by promoting the release of neurotransmitters such as acetylcholine, dopamine and norepinephrine. More particularly, the present invention relates to compounds that are capable of modulating acetylcholine receptors.
The present invention relates to novel compounds which are capable of modulating acetylcholine receptors. Invention compounds are useful, for example, for treatment of dysfunction of the central or autonomic nervous systems including dementia, cognitive disorders, neurodegenerative disorders,
The present invention relates to novel compounds which are capable of modulating acetylcholine receptors. Invention compounds are useful, for example, for treatment of dysfunction of the central or autonomic nervous systems including dementia, cognitive disorders, neurodegenerative disorders,
The present invention relates to novel compounds which are capable of modulating acetylcholine receptors. Invention compounds are useful, for example, for treatment of dysfunction of the central or autonomic nervous systems including dementia, cognitive disorders, neurodegenerative disorders,
FIELD OF THE INVENTION
The present invention relates to novel compounds which are capable of modulating acetylcholine receptors. Invention compounds are useful, for example, for treatment of dysfunction of the central or autonomic nervous systems including dementia, cognitive disorders,
FIELD OF THE INVENTION
This invention relates to a series of 1,4-dithiin- and 1,4-dithiepin-1,1,4,4-tetroxide derivatives and their use for the treatment of central nervous system disorders and affective conditions. More particularly, the compounds of the invention are ligands for the human galanin
BACKGROUND OF THE INVENTION
(1) Field of Invention
This invention relates to an effective dietary intervention plan. In one aspect all food is withheld for a period of at least 5 days, except for tropical root crops. In another aspect the invention relates to the treatment of various symptoms,
BACKGROUND OF THE INVENTION
The present invention relates to substituted imidazoline derivatives, processes for their preparation, medicaments containing these compounds, and the use of substituted imidazoline derivatives for the preparation of medicaments.
The treatment of chronic and non-chronic
CONTINUING DATA
This application is a 371 of PCT/JP08/59287 filed May 20, 2008.
TECHNICAL FIELD
The present invention relates to a medicament, and specifically to a 1-substituted tetrahydroisoquinoline compound which is useful as an active ingredient of a pharmaceutical composition for preventing
The present invention relates to compounds which potentiate neurotransmission by promoting the release of neurotransmitters such as acetylcholine, dopamine and norepinephrine. More particularly, the present invention relates to compounds that are capable of modulating acetylcholine receptors.
BACKGROUND OF THE INVENTION
The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr.sub.10 -contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor
BACKGROUND OF THE INVENTION
The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr.sub.10 -contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor